Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin DOI Creative Commons
Xianghua Quan, Jing Li, Jialin Sun

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: May 22, 2025

Doxorubicin (DOX) is a primary treatment for breast cancer (BC), but its widespread use hindered by cardiotoxicity. Pegylated liposomal doxorubicin (PLD) has been developed to enhance the efficacy of DOX and mitigate cardiotoxic effects. However, PLD associated with adverse reactions (ADRs) such as hand-foot syndrome (HFS) oral mucositis (OM), which have garnered significant attention. Although not life-threatening, HFS OM can cause severe discomfort functional impairment. Severe cases may necessitate reduced dose or even delay interrupt chemotherapy, ultimately leading decreased medication compliance. Here, we conduct an analysis risk factors during chemotherapy regimen, thus providing early warning indicators potential occurrence these in BC patients. In this study, total 395 patients receiving were enrolled. Follow-up observations towards baseline clinical characteristics exhibited. The evaluation was also performed based on Common Terminology Criteria Adverse Events (CTCAE) Version 5.0. Analysis influencing simultaneous incidence executed using univariate multivariate logistic regression analysis. Dose intensity, history cholelithiasis, ALT, AST, Hb identified related HFS. intensity reductions white blood cell (WBC) counts OM. Furthermore, increased WBC counts, cholelithiasis emerged independent concurrent This study investigated various HFS, OM, their combination undergoing offering insights prevention other cancers.

Language: Английский

Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin DOI Creative Commons
Xianghua Quan, Jing Li, Jialin Sun

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: May 22, 2025

Doxorubicin (DOX) is a primary treatment for breast cancer (BC), but its widespread use hindered by cardiotoxicity. Pegylated liposomal doxorubicin (PLD) has been developed to enhance the efficacy of DOX and mitigate cardiotoxic effects. However, PLD associated with adverse reactions (ADRs) such as hand-foot syndrome (HFS) oral mucositis (OM), which have garnered significant attention. Although not life-threatening, HFS OM can cause severe discomfort functional impairment. Severe cases may necessitate reduced dose or even delay interrupt chemotherapy, ultimately leading decreased medication compliance. Here, we conduct an analysis risk factors during chemotherapy regimen, thus providing early warning indicators potential occurrence these in BC patients. In this study, total 395 patients receiving were enrolled. Follow-up observations towards baseline clinical characteristics exhibited. The evaluation was also performed based on Common Terminology Criteria Adverse Events (CTCAE) Version 5.0. Analysis influencing simultaneous incidence executed using univariate multivariate logistic regression analysis. Dose intensity, history cholelithiasis, ALT, AST, Hb identified related HFS. intensity reductions white blood cell (WBC) counts OM. Furthermore, increased WBC counts, cholelithiasis emerged independent concurrent This study investigated various HFS, OM, their combination undergoing offering insights prevention other cancers.

Language: Английский

Citations

0